Angie You, Ph.D.
Chief Executive Officer
Angie serves as Chief Executive Officer of Amunix Pharmaceuticals Inc. Prior to joining Amunix, Dr. You served as Chief Business & Strategy Officer and Head of Commercial at Sierra Oncology (NASDAQ: SRRA), a publicly listed hematology and oncology drug development company, where she helped the company through a successful initial public offering. She also led the company’s strategic and transactional business and commercial efforts, including building its robust pipeline through acquisition and licensing of several product assets. Prior to Sierra, Dr. You served as Chief Business Officer of Aragon Pharmaceuticals, a private oncology drug discovery and development company, where she was responsible for finance, operations, human resources, and business development. At Aragon, Dr. You helped secure several rounds of financing as well as leading the business development process that resulted in the company’s acquisition by Johnson & Johnson. In previous roles, Dr. You served as Chief Business Officer at Synosia Therapeutics and Ren Pharmaceuticals. Before joining Ren Pharmaceuticals, Dr. You focused on new company formation at Venrock Ventures.
Dr. You earned a Ph.D. in Biochemistry from Harvard University and a B.A. in Chemistry from Harvard College.
Volker Schellenberger, Ph.D.
President and Chief Technology Officer
Dr. Volker Schellenberger is a co-founder of Amunix and currently serves as President and Chief Technology Officer. Dr. Schellenberger has extensive industry experience in protein engineering and drug discovery. Previously, he headed the Protein Engineering department at Genencor, where he invented combinatorial consensus mutagenesis, selection by micro-compartmentalization, as well as mutator technology. In addition, he initiated and led collaborations with Seattle Genetics that focused on antibody-enzyme fusion proteins. Prior to his work on biotherapeutics, Dr. Schellenberger directed projects optimizing enzymes for industrial applications as well as microbes for metabolic pathway engineering.
Dr. Schellenberger received his Ph.D. from Leipzig University, where he studied protease catalyzed peptide synthesis. After postdoctoral studies at the Institute for Protein Research in Pushchino (Russia), he moved to the University of Göttingen where he developed a novel method for the production of peptides from recombinant peptide-multimers. After a postdoctoral fellowship with Bill Rutter at the University of California, San Francisco, Dr. Schellenberger joined Genencor in 1994. Dr. Schellenberger is the author of over 40 scientific papers and an inventor on more than 70 issued and pending patent applications. He is also the recipient of the Karl Lohman award of the German Society of Biochemists.
Mika Derynck, M.D.
Chief Medical Officer
Dr. Derynck is the Chief Medical Officer of Amunix. She is an accomplished drug developer with over 25 years of experience in cancer research, including a 15-year career at Genentech/Roche. She has deep expertise in oncology drug development, which spans multiple therapeutic modalities, tumor types, and all phases of development. During her tenure at Genentech/Roche, she oversaw the approvals and/or global development for over a dozen drugs, including Perjeta®, Avastin®, Tecentriq®, Cotellic®, ipatasertib, taselisib, pictilisib, and apitolisib. Most recently, she served as the Global Head for Cancer Immunotherapy, GI/GU Cancers, Angiogenesis Franchises and China Oncology Development. She also served as the Co-Chair of the Cancer Immunotherapy Committee (CITC), the GI/GU Franchises Committee, and the Breast Cancer Disease Area Team. Dr. Derynck was also a Senior Group Medical Director of Exploratory Clinical Development at Genentech, serving as the development lead for multiple early-stage programs. Before Genentech, Dr. Derynck was an Assistant Clinical Professor in the UCSF Department of Cellular and Molecular Pharmacology and Division of Hematology / Oncology. Dr. Derynck holds a B.A. from Boston University and an M.D. from Boston University School of Medicine. She completed an internal medicine residency at Johns Hopkins, followed by a fellowship in Hematology / Oncology at UCSF and a postdoctoral fellowship at UCSF.
Darcy Mootz, Ph.D.
Chief Business Officer
Dr. Mootz is the Chief Business Officer of Amunix. Before joining the company, she was an independent consultant working with VCs and pharmaceutical companies on a wide range of corporate development and strategy projects. Prior to that, she served as Chief Business Officer of ORIC Pharmaceuticals, a private oncology company, where she had a broad operational role. While VP of Corporate Development at Achaogen, she helped the company complete a successful IPO, led the project team for the company’s lead Phase 3 antibiotic (now launched as ZEMDRI), and helped raise over $100M in non-dilutive capital. Earlier experiences include playing key roles in a successful M&A while at BiPar Sciences, and in a successful new indication launch for Avastin while at Genentech.
Dr. Mootz started her career in industry at L.E.K. Consulting. She earned a B.S. in Biology from Duke University and a Ph.D. in Biochemistry from Harvard University.
Senior Vice President Finance
Yvonne is a seasoned finance executive with expertise in equity financing, financial planning and analysis, technical accounting and internal controls. Over her 12-year career at OncoMed Pharmaceuticals, a public oncology company, she held increasing responsibility, most recently leading the finance group serving as the VP of Finance, Principle Financial/Accounting Officer. At OncoMed, she not only managed all aspects of the long-term business planning, but also oversaw the day-to-day accounting operations of the company, including production of financial statements and SEC filings. In addition, she oversaw other G&A functions including HR, administrative, facilities, and IT. Prior to OncoMed, she served as the Director of Finance of the Anita Borg Institute, where she managed both accounting and financial planning & analysis. Yvonne received her MBA in Finance from San Francisco State University, and she is a member of the American Institute of Certified Public Accountants.